Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant

NCT03459170 is registered in ClinicalTrials.gov with Bellicum Pharmaceuticals as lead sponsor.

NCT NCT03459170
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03459170 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and Rimiducid Infusion For Children With Recurrent Hematologic Malignancies or Minimal Residual Disease After Allogeneic Transplant
Lead sponsor
Bellicum Pharmaceuticals
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 1, 2018
Completion date
September 30, 2035
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy